NCT01400620View on ClinicalTrials.gov

Safety and Efficacy of IZN-6N4 Oral Rinse for the Prevention of Oral Mucositis in Patients With Head and Neck Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
Oral Mucositis
Interventions
DRUG

IZN-6N4

Oral rinse containing 1% botanical extracts, 15 cc rinse 3 times per day, for up to 9 weeks

Trial Locations (10)

10003

Mount Sinai Beth Israel - Phillips Ambulatory Care Center, New York

10016

NYU Clinical Cancer Center, New York

32610

UF Health Cancer Center, Gainesville

33136

University of Miami-Sylvester CCC Clinical Research Services, Miami

52621

Sheba Medical Center, Tel Litwinsky

64239

Sourasky Medical Center, Tel Aviv

Unknown

Soroka Medical Center, Beersheba

Rambam Medical Center, Haifa

Rabin Medical Center - Beilinson Campus, Petah Tikva

Assuta Medical Center, Tel Aviv

Sponsors

Lead Sponsor

Izun Pharma Ltd
All Listed Sponsors
lead

Izun Pharma Ltd

INDUSTRY

NCT01400620 - Safety and Efficacy of IZN-6N4 Oral Rinse for the Prevention of Oral Mucositis in Patients With Head and Neck Cancer | Biotech Hunter | Biotech Hunter